the path to metabolic disease
For Non-Alcoholic Fatty Liver Disease & Type 2 Diabetes
LBS-009 is a first-in-class anti-RBP4 oral therapy targeting liver disease and type 2 diabetes, two age-related metabolic diseases. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and type 2 diabetes cumulatively impact more than 1.89 billion patients worldwide. Many studies in the peer-reviewed literature have focused on the role of RBP4 in both diseases, confirming that elevated levels of RBP4 are a contributing factor. The combined projected global market for NAFLD/NASH and diabetes is $79 billion dollars.
LBS-009 is currently in preclinical development, and is expected to enter first-in-human Phase 1 clinical trials in 2020.